share_log

Ladenburg Thalmann Upgrades Aileron Therapeutics to Buy, Announces $9 Price Target

Benzinga ·  Dec 2, 2023 00:43

Ladenburg Thalmann analyst Aydin Huseynov upgrades Aileron Therapeutics (NASDAQ:ALRN) from Neutral to Buy and announces $9 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment